Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. UroGen Pharma Ltd.
  6. Company
    URGN   IL0011407140

UROGEN PHARMA LTD.

(URGN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/26 10:35:04 am
7.805 USD   -2.56%
01/18HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating
MT
01/07INSIDER SELL : Urogen Pharma
MT
01/05UroGen Pharma to Present at Upcoming Conferences
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo UroGen Pharma Ltd.
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Number of employees : 187 people.
Sales per Business
20192020Delta
Novel Solutions0.02100%11.80100% +65450%
USD in Million
Sales per region
20192020Delta
Israel0.02100%11.80100% +65450%
USD in Million
Managers
Name Title Age Since
Elizabeth Barrett President, Chief Executive Officer & Director 58 2019
Molly Henderson Chief Financial & Accounting Officer 51 2020
Moran Mieron, Dr. Director-Research & Pre-Clinical Affairs 50 -
Mark P. Schoenberg, Dr. Chief Medical Officer 63 2017
Marina Konorty, Dr. EVP-Research & Development & Technical Operations - 2020
Jason Smith Chief Compliance Officer & General Counsel - 2020
Arie Belldegrun Chairman 71 2012
Ran Nussbaum Independent Director 48 2013
Stuart Holden, Dr. Independent Director 78 2015
Kathryn Falberg Independent Director 60 2017
Members of the board
Name Title Age Since
Arie Belldegrun Chairman 71 2012
Ran Nussbaum Independent Director 48 2013
Stuart Holden, Dr. Independent Director 78 2015
Kathryn Falberg Independent Director 60 2017
Fred Ehrenkranz Cohen, Dr. Independent Director 64 2017
Cynthia M. Butitta Independent Director 66 2017
Shawn Cline Tomasello Independent Director 62 2018
Elizabeth Barrett President, Chief Executive Officer & Director 58 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 22,420,325 20,426,961 91.1% 0 0.0% 91.1%
Shareholders
NameEquities%
Menora Mivtachim Insurance Ltd. 2,954,699 13.2%
Pontifax Management Co. Ltd. 1,466,380 6.54%
Consonance Capital Management LP 1,433,774 6.39%
Moshe Arkin 1,369,315 6.11%
Credit Suisse Securities (USA) LLC (Broker) 1,085,671 4.84%
Credit Suisse Asset Management (Schweiz) AG 1,069,693 4.77%
RTW Investments LP 857,464 3.82%
ProQuest Management LLC 789,297 3.52%
Great Point Partners LLC 750,000 3.35%
Medical Strategy GmbH 741,474 3.31%
Brand Portfolio
In partnership withAllbrands.markets
More brands of UroGen Pharma Ltd.
Sector Bio Therapeutic Drugs